TherapeuticsMD (TXMD) Misses Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
TherapeuticsMD Announces Fourth Quarter 2021 Financial Results
March 10, 2022 6:50 AM EST
- Reached definitive agreement to fully divest vitaCare business unit enabling greater focus on achieving leadership position in womens healthcare -
- Amended credit terms with Sixth Street in support of a new capitalization plan -
- Conference call scheduled for 8:30 a.m. ET today -
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (TXMD or the Company) (NASDAQ: TXMD), an innovative, leading womens healthcare company, today reported financial results for the fourth quarter ended December 31, 2021.
We spent the past three months executing on four... More
